Submission of revised intimation of appointment of Additional Director.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd has submitted a revised intimation regarding the appointment of Mr. Lakshman Samala as an Additional Director (Non-Executive Independent) on the company's board, effective from February 12, 2025. The appointment was approved by the Board of Directors at their meeting held on the same date and is subject to shareholder approval. Mr. Samala holds a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology and has experience in the pharmaceutical secondary packaging materials industry. He is not related to any existing directors, key managerial personnel, or promoters of the company. He will hold office until the next general meeting of the company.
This is a routine corporate governance disclosure regarding the addition of an independent director with relevant pharmaceutical industry expertise. No immediate material impact on shareholders or stock price is expected, though it strengthens board independence.